Can GLP-1 Medications and Surgery Work Together?

Preoperative use

GLP-1 medications are sometimes used in the months leading up to bariatric or metabolic surgery to support weight reduction, improve glycemic control, or reduce hepatic steatosis when these are clinically desirable before a procedure. Anesthesiology societies have published guidance on perioperative considerations related to delayed gastric emptying; decisions about timing and any temporary discontinuation before the operating room are made by the surgical and anesthesia teams.

Postoperative use

Some patients reach a stable but suboptimal weight loss after surgery, or experience plateau. In these situations, clinicians may consider reintroducing or initiating GLP-1 therapy as an adjunct to continued nutritional and behavioral support. Published case series and emerging clinical experience describe meaningful additional weight loss when pharmacotherapy is layered onto post-surgical anatomy, though comparative trial evidence continues to evolve.

Weight regain management

A subset of patients experience weight regain in the years following bariatric surgery. The appropriate response is individualized and may include re-engagement with nutrition and behavioral teams, evaluation for anatomic causes, consideration of revisional procedures when indicated, and the addition of pharmacotherapy including GLP-1 agents. No single option is uniformly appropriate; selection depends on the cause of regain, comorbid conditions, and patient preferences.

Integrated treatment pathways

Society guidance from organizations including ASMBS and AACE increasingly frames obesity as a chronic, relapsing disease that benefits from longitudinal, multidisciplinary care. Within that framework, GLP-1 therapy and surgical procedures are tools that may be applied at different stages — sometimes sequentially, sometimes together — based on disease severity, comorbidities, and treatment response.

The decision to combine therapies is clinical and individualized. Patients considering any change to their treatment plan should discuss the options with their bariatric, metabolic, or primary care clinician.